Pharmacotherapeutics for Advanced Practice 5th Edition Test Bank – Virginia Arcangelo & Andrew Peterson – Q&A Guide

TEST BANK M



Pharmacotherapeutics for Advanced Practice: A Practical Approach
M M M M M M




by Virginia Poole Arcangelo, Andrew M. Peterson
M M M M M M


Fifth Edition
M




FULL TEST BANK!!! M M

,Chapter 1 Issues for the Practitioner in Drug Therapy
M M M M M M M M




MULTIPLEMCHOICE

1. NurseMpractitionerMprescriptiveMauthorityMisMregulatedMby:
A. TheMNationalMCouncilMofMStateMBoardsMofMNursing
B. TheMU.S.MDrugMEnforcementMAdministration
C. TheMStateMBoardMofMNursingMforMeachMstate
D. TheMStateMBoardMofMPharmacy
ANS:M C PTS:M 1

2. PhysicianMAssistantM(PA)MprescriptiveMauthorityMisMregulatedMby:
A. TheMNationalMCouncilMofMStateMBoardsMofMNursing
B. TheMU.S.MDrugMEnforcementMAdministration
C. TheMStateMBoardMofMNursing
D. TheMStateMBoardMofMMedicalMExaminers
ANS:M D PTS:M 1

3. ClinicalMjudgmentMinMprescribingMincludes:
A. FactoringMinMtheMcostMtoMtheMpatientMofMtheMmedicationMprescribed
B. AlwaysMprescribingMtheMnewestMmedicationMavailableMforMtheMdiseaseMprocess
C. HandingMoutMdrugMsamplesMtoMpoorMpatients
D. PrescribingMallMgenericMmedicationsMtoMcutMcosts

ANS:M A PTS:M 1

4. CriteriaMforMchoosingManMeffectiveMdrugMforMaMdisorderMinclude:
A. AskingMtheMpatientMwhatMdrugMtheyMthinkMwouldMworkMbestMforMthem
B. ConsultingMnationallyMrecognizedMguidelinesMforMdiseaseMmanagement
C. PrescribingMmedicationsMthatMareMavailableMasMsamplesMbeforeMwritingMaMprescription
D. FollowingMU.S.MDrugMEnforcementMAdministrationM(DEA)MguidelinesMf
orMprescribing
ANS:M B PTS:M 1

5. NurseMpractitionerMpracticeMmayMthriveMunderMhealth-careMreformMdueMto:
A. TheMdemonstratedMabilityMofMnurseMpractitionersMtoMcontrolMcostsMandMimproveMpati
entMoutcomes
B. TheMfactMthatMnurseMpractitionersMwillMbeMableMtoMpracticeMindependently
C. TheMfactMthatMnurseMpractitionersMwillMhaveMfullMreimbursementMunderMhealth-
careMreform
D. TheMabilityMtoMshiftMaccountabilityMforMMedicaidMtoMtheMstateMlevel
ANS:M A PTS:M 1

, M
lOMoAR cPSD|




M 21007614




Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
M M M M M M




MULTIPLEMCHOICE

1. AMpatient'sMnutritionalMintakeMandMlabMworkMreflectsMhypoalbuminemia.MThisMisMcritica
lMtoMprescribingMbecause:
A. DistributionMofMdrugsMtoMtargetMtissueMmayMbeMaffected
B. TheMsolubilityMofMtheMdrugMwillMnotMmatchMtheMsiteMofMabsorption
C. ThereMwillMbeMlessMfreeMdrugMavailableMtoMgenerateManMeffect
D. DrugsMboundMtoMalbuminMareMreadilyMexcretedMbyMtheMkidney

ANS:M A PTS:M 1

2. DrugsMthatMhaveMaMsignificantMfirst-passMeffect:
A. MustMbeMgivenMbyMtheMenteralM(oral)MrouteMonly
B. BypassMtheMhepaticMcirculation
C. AreMrapidlyMmetabolizedMbyMtheMliverMandMmayMhaveMlittleMifManyMdesiredMaction
D. AreMconvertedMbyMtheMliverMtoMmoreMactiveMandMfat-solubleMforms
ANS:M C PTS:M 1

3. TheMrouteMofMexcretionMofMaMvolatileMdrugMwillMlikelyMbe:
A. TheMkidneys
B. TheMlungs
C. TheMbileMandMfeces
D. TheMskin
ANS:M B PTS:M 1

4. MedroxyprogesteroneM(DepoMProvera)MisMprescribedMIMMtoMcreateMaMstorageMreservoirMof
MtheMdrug.MStorageMreservoirs:
A. AssureMthatMtheMdrugMwillMreachMitsMintendedMtargetMtissue
B. AreMtheMreasonMforMgivingMloadingMdoses
C. IncreaseMtheMlengthMofMtimeMaMdrugMisMavailableMandMactive
D. AreMmostMcommonMinMcollagenMtissues
ANS:M C PTS:M 1

5. TheMNPMchoosesMtoMgiveMcephalexinMeveryM8MhoursMbasedMonMknowledgeMofMtheMdrug's:
A. PropensityMtoMgoMtoMtheMtargetMreceptor
B. BiologicalMhalf-life
C. Pharmacodynamics
D. SafetyMandMsideMeffects

ANS:M B PTS:M 1

6. AzithromycinMdosingMrequiresMtheMfirstMday'sMdoseMbeMtwiceMthoseMofMtheMotherM4MdaysMo
fMtheMprescription.MThisMisMconsideredMaMloadingMdose.MAMloadingMdose:
A. RapidlyMachievesMdrugMlevelsMinMtheMtherapeuticMrange
B. RequiresMfourMtoMfiveMhalf-livesMtoMattain
C. IsMinfluencedMbyMrenalMfunction

, M
lOMoAR cPSD|




M 21007614




D. IsMdirectlyMrelatedMtoMtheMdrugMcirculatingMtoMtheMtargetMtissues
ANS:M A PTS:M M 1

7. TheMpointMinMtimeMonMtheMdrugMconcentrationMcurveMthatMindicatesMtheMfirstMsignMofMaMtherap
euticMeffectMisMthe:
A. MinimumMadverseMeffectMlevel
B. PeakMofMaction
C. OnsetMofMaction
D. TherapeuticMrange
ANS:M C PTS:M 1

8. PhenytoinMrequiresMaMtroughMlevelMbeMdrawn.MPeakMandMtroughMlevelsMareMdone:
A. WhenMtheMdrugMhasMaMwideMtherapeuticMrange
B. WhenMtheMdrugMwillMbeMadministeredMforMaMshortMtimeMonly
C. WhenMthereMisMaMhighMcorrelationMbetweenMtheMdoseMandMsaturationMofMreceptorMsites
D. ToMdetermineMifMaMdrugMisMinMtheMtherapeuticMrange
ANS:M D PTS:M 1

9. AMlaboratoryMresultMindicatesMtheMpeakMlevelMforMaMdrugMisMaboveMtheMminimumMt
oxicMconcentration.MThisMmeansMthatMthe:
A. ConcentrationMwillMproduceMtherapeuticMeffects
B. ConcentrationMwillMproduceManMadverseMresponse
C. TimeMbetweenMdosesMmustMbeMshortened
D. DurationMofMactionMofMtheMdrugMisMtooMlong

ANS:M B PTS:M 1

10. DrugsMthatMareMreceptorMagonistsMmayMdemonstrateMwhatMproperty?
A. IrreversibleMbindingMtoMtheMdrugMreceptorMsite
B. Up-regulationMwithMchronicMuse
C. DesensitizationMorMdown-regulationMwithMcontinuousMuse
D. InverseMrelationshipMbetweenMdrugMconcentrationMandMdrugMaction

ANS:M C PTS:M 1

11. DrugsMthatMareMreceptorMantagonists,MsuchMasMbetaMblockers,MmayMcause:
A. Down-regulationMofMtheMdrugMreceptor
B. AnMexaggeratedMresponseMifMabruptlyMdiscontinued
C. PartialMblockadeMofMtheMeffectsMofMagonistMdrugs
D. AnMexaggeratedMresponseMtoMcompetitiveMdrugMagonists
ANS:M B PTS:M 1

12. FactorsMthatMaffectMgastricMdrugMabsorptionMinclude:
A. LiverMenzymeMactivity
B. Protein-bindingMpropertiesMofMtheMdrugMmolecule
C. LipidMsolubilityMofMtheMdrug
D. AbilityMtoMchewMandMswallow
ANS:M C PTS:M 1




WWW.TEGTBANKTANK.COM